Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Asset Writedowns and Impairment (2016 - 2023)

BioCorRx's Asset Writedowns and Impairment history spans 6 years, with the latest figure at $47980.0 for Q1 2023.

  • For Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $47980.0; the TTM value through Dec 2023 reached $47980.0, changed N/A, while the annual FY2023 figure was $47980.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q1 2023 was $47980.0 at BioCorRx, up from $3400.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $47980.0 in Q1 2023 and bottomed at -$1000.0 in Q1 2019.